342 related articles for article (PubMed ID: 18187663)
21. Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
Xiong J; Su T; Qu Z; Yang Q; Wang Y; Li J; Zhou S
Oncotarget; 2016 Apr; 7(17):23933-46. PubMed ID: 27004407
[TBL] [Abstract][Full Text] [Related]
22. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
Panichakul T; Intachote P; Wongkajorsilp A; Sripa B; Sirisinha S
Anticancer Res; 2006; 26(1A):259-65. PubMed ID: 16475706
[TBL] [Abstract][Full Text] [Related]
23. TRAIL and triptolide: an effective combination that induces apoptosis in pancreatic cancer cells.
Borja-Cacho D; Yokoyama Y; Chugh RK; Mujumdar NR; Dudeja V; Clawson KA; Dawra RK; Saluja AK; Vickers SM
J Gastrointest Surg; 2010 Feb; 14(2):252-60. PubMed ID: 20013316
[TBL] [Abstract][Full Text] [Related]
24. Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
Singh AK; Chauhan SS; Singh SK; Verma VV; Singh A; Arya RK; Maheshwari S; Akhtar MS; Sarkar J; Rangnekar VM; Chauhan PMS; Datta D
Carcinogenesis; 2016 Nov; 37(11):1027-1040. PubMed ID: 27543608
[TBL] [Abstract][Full Text] [Related]
25. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells.
Carter BZ; Mak DH; Schober WD; McQueen T; Harris D; Estrov Z; Evans RL; Andreeff M
Blood; 2006 Jul; 108(2):630-7. PubMed ID: 16556893
[TBL] [Abstract][Full Text] [Related]
26. Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation.
Chen L; Meng Y; Sun Q; Zhang Z; Guo X; Sheng X; Tai G; Cheng H; Zhou Y
Cell Death Dis; 2016 Aug; 7(8):e2334. PubMed ID: 27512955
[TBL] [Abstract][Full Text] [Related]
27. Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation.
Zhou J; Lu GD; Ong CS; Ong CN; Shen HM
Mol Cancer Ther; 2008 Jul; 7(7):2170-80. PubMed ID: 18645026
[TBL] [Abstract][Full Text] [Related]
28. MAPKs are not involved in triptolide-induced cell growth inhibition and apoptosis in prostate cancer cell lines with different p53 status.
Li W; Liu Y; Li XX; Yu Y; Wu JJ; Wang Q; Huo H; Wang LM; Yang L
Planta Med; 2011 Jan; 77(1):27-31. PubMed ID: 20607649
[TBL] [Abstract][Full Text] [Related]
29. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
Zauli G; Celeghini C; Melloni E; Voltan R; Ongari M; Tiribelli M; di Iasio MG; Lanza F; Secchiero P
Haematologica; 2012 Nov; 97(11):1722-30. PubMed ID: 22689683
[TBL] [Abstract][Full Text] [Related]
30. Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells.
Tseng HY; Jiang CC; Croft A; Tay KH; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD
Mol Cancer Ther; 2010 Dec; 9(12):3363-74. PubMed ID: 21159614
[TBL] [Abstract][Full Text] [Related]
31. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells.
Yano K; Horinaka M; Yoshida T; Yasuda T; Taniguchi H; Goda AE; Wakada M; Yoshikawa S; Nakamura T; Kawauchi A; Miki T; Sakai T
Int J Oncol; 2011 Feb; 38(2):365-74. PubMed ID: 21165560
[TBL] [Abstract][Full Text] [Related]
32. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
[TBL] [Abstract][Full Text] [Related]
33. Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.
Sai K; Li WY; Chen YS; Wang J; Guan S; Yang QY; Guo CC; Mou YG; Li WP; Chen ZP
Am J Chin Med; 2014; 42(2):485-503. PubMed ID: 24707876
[TBL] [Abstract][Full Text] [Related]
34. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells.
Kiviharju TM; Lecane PS; Sellers RG; Peehl DM
Clin Cancer Res; 2002 Aug; 8(8):2666-74. PubMed ID: 12171899
[TBL] [Abstract][Full Text] [Related]
35. Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 balance.
Li M; Zhang X; Zhou WJ; Chen YH; Liu H; Liu L; Yang CM; Qan WB
Acta Pharmacol Sin; 2013 Dec; 34(12):1545-53. PubMed ID: 24241349
[TBL] [Abstract][Full Text] [Related]
36. Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway.
Trivedi R; Maurya R; Mishra DP
Cell Death Dis; 2014 Oct; 5(10):e1465. PubMed ID: 25321472
[TBL] [Abstract][Full Text] [Related]
37. Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.
Ding J; Polier G; Köhler R; Giaisi M; Krammer PH; Li-Weber M
J Biol Chem; 2012 Jan; 287(1):641-649. PubMed ID: 22086925
[TBL] [Abstract][Full Text] [Related]
38. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL.
Meijer A; Kruyt FA; van der Zee AG; Hollema H; Le P; ten Hoor KA; Groothuis GM; Quax WJ; de Vries EG; de Jong S
Br J Cancer; 2013 Nov; 109(10):2685-95. PubMed ID: 24136147
[TBL] [Abstract][Full Text] [Related]
39. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
Bullenkamp J; Raulf N; Ayaz B; Walczak H; Kulms D; Odell E; Thavaraj S; Tavassoli M
Cell Death Dis; 2014 Oct; 5(10):e1489. PubMed ID: 25341043
[TBL] [Abstract][Full Text] [Related]
40. Triptolide sensitizes human breast cancer cells to tumor necrosis factor‑α‑induced apoptosis by inhibiting activation of the nuclear factor‑κB pathway.
Cheng X; Shi W; Zhao C; Zhang D; Liang P; Wang G; Lu L
Mol Med Rep; 2016 Apr; 13(4):3257-64. PubMed ID: 26935527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]